Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 04, 2015 2:55 AM ET

Healthcare Providers and Services

Company Overview of 21st Century Oncology Holdings, Inc.

Company Overview

21st Century Oncology Holdings, Inc., together with its subsidiaries, operates as a physician-led provider of integrated cancer care services. Its radiation treatment services include external beam therapies, such as conformal radiation therapy, intensity modulated radiation therapy, and stereotactic radiosurgery, as well as internal radiation therapies, such as high-dose and low-dose rate brachytherapies. The company’s radiation treatment services also comprise image guided radiation therapy, Gamma function testing, and respiratory gating. In addition, it offers support services in the areas of psychological and nutritional counseling, as well as transportation assistance. Further, the comp...

2270 Colonial Boulevard

Fort Myers, FL 33907

United States

Founded in 1983

4,630 Employees



Key Executives for 21st Century Oncology Holdings, Inc.

Co-Founder, Chief Executive Officer, President, Executive Director, Member of Executive Committee, Member of Capital Allocation Committee, President of Radiation Therapy Services Inc. and Chief Executive Officer of Radiation Therapy Services Inc
Age: 62
Principal Financial Officers, Chief Accounting Officer, Senior Vice President, Corporate Controller and Assistant Treasurer
Age: 46
Chief Executive Officer of Medical Developers Cooperatief U A B V, Chief Executive Officer of Vidt Centro Medico, President of Medical Developers Cooperatief U A B V and President of Vidt Centro Medico
Age: 56
Chief Medical Officer
Age: 46
Chief Compliance Officer and Senior Vice President
Age: 63
Compensation as of Fiscal Year 2015.

21st Century Oncology Holdings, Inc. Key Developments

21st Century Oncology Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Confirms Financial Guidance for the Full Year of 2015

21st Century Oncology reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. Total pro forma first quarter of 2015 revenues were $278.5 million, compared to total pro forma revenues of $242.2 million in the same quarter of 2014, a year-over-year increase of 15%. Pro forma adjusted EBITDA for the first quarter of 2015 was $43.7 million or 15.7% of total pro forma revenues, up 39.4% year-over-year, compared to $31.3 million or 12.9% of total pro forma revenues in the first quarter of 2014. The increase was primarily due to the contributions from Oncure and SFRO, improved operational efficiency, as well as its results from the company's recently enacted expense management initiatives. Net loss for the first quarter of 2015 was $12.9 million, compared to a net loss of $29.2 million in the first quarter of 2014. Same-store treatments grew nicely at 3.9% rate, even exceeding last year's 3.4% same-store growth. The first quarter of 2015 produced solid revenue growth, driven by healthy organic growth, contributions from the recent joint ventures and health system affiliations, strong international results, and continued expansion of its ICC model. Total cash expenditures were reduced over 1/3 from $19.1 million for the quarter ended March 31, 2014, compared to $12.3 million for the quarter ended March 31, 2015. The reduced level of capital expenditures was expected due to the completion of the Oncure integration in 2014. Net cash provided by operating activities was $22,739,000 compared to net cash used in operating activities of $305,000 a year ago. Purchase of property and equipment was $12,265,000 compared to $19,063,000 a year ago. Total revenues were $278,483,000 compared to $233,397,000 a year ago. Loss before income taxes was $10,244,000 compared to $27,139,000 a year ago. Net loss attributable to the company's shareholder was $15,242,000 compared to $30,181,000 a year ago. As a result of its strong quarter results, the company is confirming full year 2015 total pro forma adjusted EBITDA guidance of between $182 million to $190 million.

21st Century Oncology Holdings, Inc., Q1 2015 Earnings Call, May 13, 2015

21st Century Oncology Holdings, Inc., Q1 2015 Earnings Call, May 13, 2015

21st Century Oncology Holdings, Inc. to Report Q1, 2015 Results on May 12, 2015

21st Century Oncology Holdings, Inc. announced that they will report Q1, 2015 results After-Market on May 12, 2015

Similar Private Companies By Industry

Company Name Region
Stratford Commons, Inc. United States
Seattle Biomedical Research Institute United States
Lowe BioCore Communications United States
The Rehabilitation Hospital of South Jersey United States
The Phoenix Ophthalmology ASC, LLC United States

Recent Private Companies Transactions

April 21, 2015
Maddock Center for Radiation Oncology
Private Placement
September 26, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 21st Century Oncology Holdings, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at